Why the Cyclopharm (ASX:CYC) share price popped 6% today

The Cyclopharm share price went soaring today as the company announced a market update. We take a closer look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cyclopharm Limited (ASX: CYC) share price was sent soaring today after the company announced a business update.

Cyclopharm shares went as high as 14.41% in afternoon trade before closing 6.78% up at $2.52 per share.

What Cyclopharm does

Cyclopharm is an ASX-listed radiopharmaceutical company headquartered in New South Wales. It currently has a market capitalisation of just over $203 million.

As stated on the company's website, "the company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes."

The health company aims to achieve this objective through the provision of its core radiopharmaceutical product, Technegas, which is used in functional lung ventilation imaging.

What happened?

Today, the Cyclopharm share price went soaring after the company announced an update on its progress towards gaining United States Food and Drug Administration (USFDA) approval. The company needs USFDA approval in order to begin sales of Technegas, its flagship product, in the US.

The company announced that its phase 3 trials have met their Primary and Secondary Efficacy Endpoints in September of last year. As such, it will continue its ongoing "positive" dialogue with the USFDA in order to get its approval of Technegas.

Based on these discussions, the company remains highly confident the approval process is on track to be completed in the second half of FY21.

Cyclopharm also updated its guidance for FY20 revenue. The company stated that despite the challenges of COVID-19, revenue is expected to be in line with that of FY19, which was approximately $14 million.

US market entry

With the impending approval of Technegas, Cyclopharm has begun undertaking activities to ensure it is well placed to rapidly roll out its product. These activities include building inventory reserves, finalising agreements for third party distribution, service and installation, and administrative support.

According to Cyclopharm, the existing market for nuclear medicine ventilation in the US is estimated to be roughly US$90 million annually.

Based on Cyclopharm's experience in the Canadian market, it remains confident that Technegas can achieve a 50% share of the USA market over 2 to 3 years, with an 80% share representing around 480,000 procedures per annum achievable over a 5 to 7 year period.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares can rise 20% to 50%

Let's see which shares are being tipped to rocket from current levels.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors panicked when the latest inflation figures came out today.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Broker Notes

Why Guzman Y Gomez shares are a sell

Goldman Sachs has given its verdict on the burrito seller.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Mac Copper, Pro Medicus, Web Travel, and Yancoal shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why ALS, Fisher & Paykel Healthcare, IPD, and Predictive Discovery shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

Man looking at his grocery receipt, symbolising inflation.
Share Market News

How are ASX 200 investors responding to the latest Aussie inflation numbers?

The ASX 200 was up 0.2% today before the ABS reported the latest inflation figures.

Read more »

A couple makes silly chip moustache faces and take a selfie on their phone.
Broker Notes

Macquarie sees more upside in Telstra shares – What are they worth?

Telstra shares are up 34% over the past year, and Macquarie thinks there's more to come.

Read more »